ArticleThe mental health clinician2026
Examining individual serotonin and norepinephrine reuptake inhibitors and fall-related hospitalizations in older adults.
Article in The mental health clinician, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence of falls in a pooled US cohort of adults with systemic lupus erythematosus: a nested cross-sectional study.Lupus science & medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: MDD is often managed with antidepressants that may carry a fall risk. Limited data exist comparing fall risk across individual SNRIs. Therefore, this study aimed to determine the fall rates associated with SNRIs. Methods: Data were drawn from Merative MarketScan Medicare Supplemental claims (January 1, 2015 to November 30, 2021), including adults 65 years and older prescribed an SNRI (ie, duloxetine, venlafaxine, desvenlafaxine, milnacipran, levomilnacipran). The index date was the first prescription claim. Patients were followed up to 1 month after their last prescription to identify falls, using International Classification of Diseases (ICD) 9 Results: A total of 79 256 patients met eligibility (68% female; mean age: 75 years). Duloxetine (66%) and venlafaxine (30%) were the most prescribed. The overall fall rate was approximately 1% with duloxetine having the highest (1.1%), and venlafaxine having the lowest rate (0.68%). Injuries occurred in 79% of fall cases. After adjusting for age, sex, and comorbidities, the odds ratio for falling with venlafaxine versus duloxetine was 0.69 (95% CI = 0.56, 0.83), indicating a 31% odds reduction with venlafaxine compared with duloxetine. Discussion: Venlafaxine appears to have a lower fall risk than duloxetine. Further studies are needed to determine clinical significance and assess fall-related costs to support safer SNRI use in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.